Results-driven Medical Affairs professional with a proven track record in driving scientific and clinical initiatives.As a seasoned Medical Affairs leader, I excel in developing and implementing effective strategies that drive scientific and clinical excellence. My deep understanding of the drug and medical device development processes, coupled with my strong analytical skills and strategic thinking, enables me to consistently deliver impactful results. I am adept at collaborating with cross-functional teams to align medical affairs objectives with broader business goals, ensuring that our efforts contribute to the advancement of patient care.My expertise lies in:Clinical Trial Management: Overseeing clinical trials from inception to completion, ensuring adherence to regulatory guidelines and data integrity.Scientific Communication: Effectively communicating complex scientific information to internal and external stakeholders, including healthcare professionals and patients.Data Analysis: Leveraging data analytics to identify trends, inform decision-making, and optimise medical affairs activities.Strategic Partnerships: Building and maintaining strong relationships with key stakeholders, including healthcare providers, regulatory authorities, and industry partners.I am also the discoverer of a novel drug candidate (eCF506, now known as NXP900), which I developed during my PhD. This innovative compound, designed to target specific pathways involved in tumour growth and progression, is currently being evaluated in a Phase 1 clinical trial in patients with solid tumours. The successful development of this drug candidate has the potential to significantly impact the treatment landscape for patients with refractory cancers.